Work

Identification of STX-721, an EGFR exon 20 mutant inhibitor with superior selectivity and a potential best-in-class profile

Year: 2022

Type: article

Source: European Journal of Cancer

DOI: 10.1016/s0959-8049(22)00880-2

Authors: R. Pagliarini, B.C. Milgram, D.R. Borrelli, N. Brooijmans, M.R. Huff, T. Ito, P. Jonsson, B. Ladd, E. O’Hearn, W. Wang, P. Kuzmic, J. Bellier, A.N. Hata, A. Guzman-Perez, D.D. Stuart

Institutions: Scorpion Therapeutics (United States), Harvard University, Massachusetts General Hospital

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4307909019

FWCI: 0.422

Cites:

Cited by: 3

Related to: 10